Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8749655 | 1.00 | MAOB (0.52) | MAOBALDH1A1NR5A1TSHRTP53 | |
| SCHEMBL5106446 | 0.98 | MAOB (0.50) | MAOBALDH1A1NR5A1TSHRTP53 | |
| SCHEMBL4064858 | 0.95 | ALDH1A1 (0.51) | MAOBALDH1A1 | |
| SCHEMBL4067770 | 0.92 | MDM2 (0.50) | MAOBALDH1A1 | |
| SCHEMBL14195830 | 0.91 | MAOB (0.62) | MAOBALDH1A1NR5A1PLA2G4BTHRA | |
| SCHEMBL4063273 | 0.91 | MAOB (0.62) | MAOBALDH1A1NR5A1PLA2G4BTHRA | |
| SCHEMBL8702506 | 0.91 | ALDH1A1 (0.61) | MAOBALDH1A1THRATHRB | |
| SCHEMBL17558110 | 0.91 | MAOB (0.46) | MAOBALDH1A1PLA2G4B | |
| SCHEMBL17558112 | 0.91 | MAOB (0.46) | MAOBALDH1A1PLA2G4B | |
| SCHEMBL19399340 | 0.89 | MAOB (0.45) | MAOBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778621-B1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO LTD (JP) | 2023-08-23 | — | — | EP | claimed |
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182268-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-3778621-B1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO LTD (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-113045628-B | Application of antibacterial peptide or variant thereof in preparation of antibacterial product | 山东大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-3778621-A1 | PEPTIDE SYNTHESIS METHOD | Jitsubo Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | disclosed |
| US-8293948-B2 | Reagent for organic synthesis and method of organic synthesis reaction with the reagent | JITSUBO CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20120108788-A1 | REAGENT FOR ORGANIC SYNTHESIS AND METHOD OF ORGANIC SYNTHESIS REACTION WITH THE REAGENT | JITSUBO CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8093435-B2 | Reagent for organic synthesis and method of organic synthesis reaction with the reagent | JITSUBO CO., LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090299103-A1 | Reagent for Organic Synthesis and Method of Organic Synthesis Reaction with the Reagent | NATIONAL UNIVERSITY CORPORATION, TOKYO UNIVERSITY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299103-A1 | Reagent for Organic Synthesis and Method of Organic Synthesis Reaction with the Reagent | COASY, OSTC, OGA | MAOB 260/4885ALDH1A1 1146/4885NR5A1 2629/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | MAOB 2667/4885ALDH1A1 4056/4885NR5A1 2010/4885 |
| US-20120108788-A1 | REAGENT FOR ORGANIC SYNTHESIS AND METHOD OF ORGANIC SYNTHESIS REACTION WITH THE REAGENT | COASY, OSTC, OGA | MAOB 260/4885ALDH1A1 1146/4885NR5A1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.